Friday January 19th 2018

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Source article:  

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Leave a Comment

More from category

Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases

An international team of researchers led by prof. Savvas Savvides has unraveled a crucial aspect of the molecular basis [Read More]

Kessler Foundation wins $735,000 grant for training rehabilitation researchers
Kessler Foundation wins $735,000 grant for training rehabilitation researchers

Guang Yue, PhD, director of Human Performance and Engineering Research at Kessler Foundation, has been awarded a [Read More]

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]